Brief: Pharmaust Partners With Berry Consultants For Phase 2/3 MND Study
16/01/2024 24:15
Jan 16 (Reuters) - Pharmaust Ltd PAA.AX :
* PARTNERS WITH BERRY CONSULTANTS FOR PHASE 2/3 MND STUDY
Source text for Eikon: ID:nASX43l1Kw
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO